Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-16 agomiR
- Development stage
- Preclinical
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous (in Preclinical Models), Unspecified In Humans
01
Overview
miR-16 agomiR is a synthetic, chemically modified RNA oligonucleotide designed to mimic the endogenous microRNA miR-16. It is used to increase miR-16 expression in vitro and in vivo for research and potential therapeutic purposes. miR-16 is a microRNA with established tumor suppressor functions, but it also regulates fibrosis, inflammation, and atherosclerosis by targeting multiple signaling pathways and genes involved in extracellular matrix synthesis, degradation, and inflammatory cytokine release. Overexpression of miR-16 via agomiR inhibits pro-inflammatory cytokines (e.g., IL-6, TNF-α, MCP-1, IL-1β), promotes anti-inflammatory cytokines (e.g., IL-10), and reduces extracellular matrix deposition, potentially alleviating organ fibrosis and atherosclerosis[1][2]. The exact mechanisms vary by tissue and disease context.
- Other names
- miR-16 agomirmiR16 agomirmiR 16 agomir
02
Targets
PR domain zinc finger protein 4 messenger RNA 3'-untranslated regionBCL-2 (BCL-2 family)Microtubule-associated protein 7 (MAP7) mRNA 3'-untranslated region (3'-UTR)Wnt family member 3A messenger RNA 3'-untranslated region (WNT3A mRNA 3'-UTR)RICTORCDP-diacylglycerol synthase 2 mRNA 3'-untranslated regionCyclin-dependent kinase 6 messenger RNA 3' untranslated region (CDK6 mRNA 3' UTR)Sal-like protein 4 messenger RNA 3' untranslated region (SALL4 mRNA 3'-UTR)CCND1 (Cyclin D1)Cyclin E1 messenger RNA 3'-untranslated region (CCNE1 mRNA 3'-UTR)
Beyond the preview
Go deeper on miR-16 agomiR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-16 agomiR.